Skip to main content

The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders

European Archives of Psychiatry and Clinical Neuroscience volume 254, pages 356–361 (2004)Cite this article

Abstract

Aims of the study

To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD).

Method

The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge.

Result

The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9% for the conventional treatment (p=0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C. I. 0.6–4.1, p < 0.001); and general psychopathology (4.0, 95% C.I. 0.8–7.2, p < 0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6% versus 56.3%; Schooler & Kane: 16.3% versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3% for olanzapine (2/87), and 16.7% (12/72) for the conventional treatment.

Conclusions

The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Beasley CM, Hamilton S, Crawford AM, et al. (1997) Olanzapine versus Haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7:125–137

    Google Scholar 

  2. Beasley CM, Dellva MA, Tamura RN, et al. (1999) Randomized double blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long term treatment with olanzapine or haloperidol. Br J Psychiatry 174:23–30

    CAS  PubMed  Google Scholar 

  3. Bymaster FP, Calligaro DO, Falcone JF, et al. (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14(2):87–96

    Article  CAS  PubMed  Google Scholar 

  4. Duggan L, Fenton M, Dardennes RM, et al. (2003) Olanzapine for schizophrenia. Cochrane Database Syst Rev (1):CD001359

    Google Scholar 

  5. Glazer WM, Morgenstern H, Doucette JT (1993) Predicting the long term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 54:133–139

    CAS  PubMed  Google Scholar 

  6. Glazer WM (2000) Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61(Suppl 4):15–20

    Google Scholar 

  7. Guy W (1976) Psychopharmacology Research Branch, NIMH. Abnormal Involuntary Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No (ADM) 76–338. Rockville, MD: National Institute of Mental Health, pp 534–537

  8. Hotopf M, Churchill R, Lewis G (1999) Pragmatic randomized controlled trials in psychiatry. Br J Psychiatry 175:217–223

    CAS  PubMed  Google Scholar 

  9. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D-2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360–369

    Article  CAS  PubMed  Google Scholar 

  10. Kapur S, Remington G (2001) Dopamine D-2 receptors and their role in atypical antipsychotic action: Still necessary and may even be sufficient. Biol Psychiatry 50(11):873–883

    Article  CAS  PubMed  Google Scholar 

  11. Kay SR, Opler LA, Fizbein A (1986) Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, New York, Multi Health Systems, Inc

  12. Leitão R, Ferraz MB, Mari JJ (2002) A prevalence based cost of illness study of schizophrenia in São Paulo State, Brazil. Schizophr Res 53(Suppl 3):259

    Google Scholar 

  13. Lingjaerde O, Ahlfors UG, Bech P, et al. (1987) The UKU side effect rating scale. Acta Psychiatr Scand 76(Suppl 334):1–100

    Google Scholar 

  14. Llorca PM, Chereeau I, Bayle F, et al. (2002) Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 17:129–138

    Article  PubMed  Google Scholar 

  15. Loza N, El-Dosoky AM, Okasha TA, et al. (1999) Olanzapine compared to chlorpromazine in acute schizophrenia. Eur Neuropsychopharmacol 9(Suppl 5):291

    Google Scholar 

  16. Mitchell IJ, Cooper AC, Griffiths MR, et al. (2002) Acute administration of haloperidol induces apoptosis of neuron in the striatum and substantia nigra in the rat. Neuroscience 109(1):89–99

    Google Scholar 

  17. Morgenstern H, Glazer WM (1993) Identifying risk factors for tardive dyskinesia among chronic outpatients maintained on neuroleptic medications: results of the Yale tardive dyskinesia study. Arch Gen Psychiatry 50:723–733

    CAS  PubMed  Google Scholar 

  18. Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia (letter). Arch Gen Psychiatry 39:486–487

    CAS  Google Scholar 

  19. Seeman P, Tallerico T (1998) Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3(2):123–134

    CAS  PubMed  Google Scholar 

  20. Seeman P (2002) Atypical antipsychotics: Mechanism of action. Can J Psychiatry 47(1):27–38

    PubMed  Google Scholar 

  21. Tollefson GD, Beasley CM, Tran PV, et al. (1997a) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154(4):457–465

    CAS  Google Scholar 

  22. Tollefson GD, Beasley CM, Tamura RN et al. (1997b) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154(9):1248–1254

    CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Universidade Federal de São Paulo, Departamento de Psiquiatria, Rua Botucatu, 740, CEP 04023-900, São Paulo, Brazil

    Jair de Jesus Mari M.D., Ph.D. & A. Niccolai Costa M.Sc.

  2. Department of Psychiatry, Federal University of Pelotas & Catholic University of Pelotas, Eli Lilly, Brazil

    M. S. Lima M.D., Ph.D.

  3. Hospital Anna Rech, Caxias do Sul, Rio Grande do Sul, Brazil

    N. Alexandrino M.D.

  4. Pax Clinica Psiquiatrica in Goiania, Goias, Brazil

    S. Rodrigues–Filho M.D.

  5. Department of Neuropsychiatry and Neurology, Federal University of Bahia, Bahia, Brazil

    I. Reis de Oliveira M.D., Ph.D.

  6. Lilly research Laboratories, Brazil

    G. D. Tollefson M.D., Ph.D.

Authors
  1. Jair de Jesus Mari M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. S. Lima M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Niccolai Costa M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Alexandrino M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Rodrigues–Filho M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. Reis de Oliveira M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. D. Tollefson M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jair de Jesus Mari M.D., Ph.D..

Rights and permissions

Reprints and Permissions

About this article

Cite this article

de Jesus Mari, J., Lima, M.S., Niccolai Costa, A. et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders . Eur Arch Psychiatry Clin Neurosci 254, 356–361 (2004). https://doi.org/10.1007/s00406-004-0514-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-004-0514-1

Key words

  • schizophrenia
  • tardive dyskinesia
  • randomized controlled trial
  • olanzapine
  • typical antipsychotic